Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 9, 23 | -0.86 Increased by +64.17% | -1.16 Increased by +25.86% |
Aug 10, 23 | -0.87 Increased by +95.56% | -1.42 Increased by +38.73% |
May 15, 23 | -1.34 Increased by +81.39% | -1.5 Increased by +10.67% |
Mar 30, 23 | -0.92 Increased by +87.22% | -3.08 Increased by +70.13% |
Nov 9, 22 | -2.4 Increased by +73.33% | -5.5 Increased by +56.36% |
Aug 11, 22 | -19.6 Decreased by -104.17% | -7.5 Decreased by -161.33% |
May 16, 22 | -7.2 Increased by +21.74% | -7.6 Increased by +5.26% |
Mar 15, 22 | -7.2 Increased by +50.68% | -8.8 Increased by +18.18% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 23 | 0 Decreased by N/A% | -3.2 M Increased by +23.26% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0 Decreased by N/A% | -3.26 M Increased by +96.68% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0 Decreased by N/A% | -4.15 M Increased by +47.72% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0 Decreased by N/A% | -110.78 M Decreased by -1.33 K% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0 Decreased by N/A% | -4.18 M Increased by +55.82% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0 Decreased by N/A% | -98.31 M Decreased by -859.04% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 0 Decreased by N/A% | -7.94 M Increased by +17.89% | Decreased by N/A% Decreased by N/A% |
Dec 31, 21 | 0 Decreased by N/A% | -7.76 M Increased by +49.62% | Decreased by N/A% Decreased by N/A% |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.